Aquilo Capital Management

Latest statistics and disclosures from Aquilo Capital Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are XBI, DRNA, ANAB, QURE, SPRO, and represent 71.24% of Aquilo Capital Management's stock portfolio.
  • Added to shares of these 10 stocks: XBI (+$112M), BPMC (+$25M), RGNX (+$10M), ARGX (+$8.1M), QURE (+$8.0M), DRNA (+$5.5M), ARWR (+$5.5M), ANAB, SPRO, NGM.
  • Started 2 new stock positions in BPMC, ARGX.
  • Reduced shares in these 2 stocks: XENE (-$17M), MRUS (-$9.3M).
  • Sold out of its positions in XENE, MRUS.
  • Aquilo Capital Management was a net buyer of stock by $154M.
  • Aquilo Capital Management has $496M in assets under management (AUM), growing by 93.28%.

Portfolio Holdings for Aquilo Capital Management

Companies in the Aquilo Capital Management portfolio as of the June 2020 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Spdr Ser Tr S&p Biotech Unit Put Option (XBI) 45.1 $224M +100% 2.0M 111.95
Dicerna Pharmaceuticals (DRNA) 7.5 $37M +17% 1.5M 25.40
Anaptysbio Inc Common (ANAB) 7.2 $36M +10% 1.6M 22.34
Uniqure Nv SHS (QURE) 6.2 $31M +35% 680k 45.06
Spero Therapeutics (SPRO) 5.3 $26M +6% 1.9M 13.53
Blueprint Medicines (BPMC) 5.0 $25M NEW 315k 78.00
Arrowhead Pharmaceuticals (ARWR) 4.9 $24M +29% 563k 43.19
Ngm Biopharmaceuticals (NGM) 4.4 $22M +4% 1.1M 19.74
Regenxbio Inc equity us cm (RGNX) 4.1 $20M +102% 554k 36.83
Pieris Pharmaceuticals (PIRS) 3.5 $17M 5.6M 3.10
Proqr Thrapeutics N V Shs Euro (PRQR) 2.9 $15M 2.4M 6.08
Galapagos Nv Spon Adr (GLPG) 1.8 $8.7M 44k 197.29
Argenx Se Sponsored Adr (ARGX) 1.6 $8.1M NEW 36k 225.22
Morphosys Sponsored Ads (MOR) 0.6 $3.0M 96k 31.67

Past Filings by Aquilo Capital Management

SEC 13F filings are viewable for Aquilo Capital Management going back to 2018